Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
17.10
0.00 (0.00%)
At close: Jan 23, 2026

HKG:3378 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Net Income
-115.83-76.06
Depreciation & Amortization
5.371.01
Other Amortization
0.110.03
Loss (Gain) From Sale of Investments
-1.6233.1
Stock-Based Compensation
22.3515.49
Other Operating Activities
-7.28-20.62
Change in Accounts Payable
-0.640.88
Change in Other Net Operating Assets
-7.35-5.83
Operating Cash Flow
-104.89-51.99
Capital Expenditures
-6.21-4.23
Sale (Purchase) of Intangibles
--0.55
Investment in Securities
99.9194.63
Other Investing Activities
2.924.11
Investing Cash Flow
96.6293.96
Long-Term Debt Repaid
-3.81-1.16
Net Debt Issued (Repaid)
-3.81-1.16
Issuance of Common Stock
12.8491.38
Other Financing Activities
-2.55-
Financing Cash Flow
6.4990.22
Foreign Exchange Rate Adjustments
10.03
Net Cash Flow
-0.79132.21
Free Cash Flow
-111.1-56.23
Free Cash Flow Margin
-5052.48%-2214.49%
Free Cash Flow Per Share
-10.16-7.71
Cash Income Tax Paid
5.812.05
Levered Free Cash Flow
101.65-
Unlevered Free Cash Flow
107.51-
Change in Working Capital
-7.99-4.95
Source: S&P Global Market Intelligence. Standard template. Financial Sources.